Acrivon Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
Business Address
480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
Mailing Address
480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
Phone
617-207-8979
Fiscal Year End
1231
EIN
825125532
Financial Overview
FY2025
$196.59M
Total Assets
$176.79M
Stockholders' Equity
$41.50M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D/A Beneficial ownership amendment | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Clinical-stage biotech developing DNA repair-targeting drugs ACR-368 (Phase 2) and ACR-2316 (Phase 1) for cancer.
- Utilizes proprietary Acrivon Predictive Precision Proteomics (AP3) platform to identify specific patient populations, aiming to boost trial success.
Insider Trading
BUY
3 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.